الفهرس 
• Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
An estimated 170 million people have chronic hepatitis C virus (HCV)
infection. With current treatment success rates, by 2030, more than 40%
will be cirrhotic and the number of cases with end-stage liver disease is
projected to treble.
Current standard-of-care is the combination of pegylated interferon plus
ribavirin for 24–48 weeks. Unfortunately this is associated with poor
efficacy (45% in HCV GT1; 75% in GT2 and 65% in GT 3) and
tolerability.
Many patients are either unsuitable for or uncompliant with current
treatment infection because of the significant side-effects associated with
this treatment, including those with decompensated cirrhosis or sever
psychiatric illness. It is hoped that the development of direct acting
antiviral agents (DAAs) will address this huge unmet medical need.
The addition of a protease inhibitor to pegylated interferon plus ribavirin
is associated with increase in efficacy and shortened duration of therapy
in patients with HCV GT1 and is likely to become the new standard-ofcare.
However, triple therapy will not be suitable for patients with non-1
HCV infection, or contraindications to interferon.
It is hoped that the combination of multiple DAAs which target different
steps of HCV replication should provide interferon-free treatment
regimen. Current and planned studies will determine which combination
(protease, nonnucleoside polymerase, nucleoside polymerase, NS5A,
cyclophyllin B inhibitors), how many DAAs and duration of therapy will
be required to optimise cure. It will also be important to minimise the
emergence of multi-resistance, which would jeopardise future retreatment
options.